In the broadly defined population of metformin-treated T2DM patients (cohort 1), the HE3286 responsive patient population was found in the upper two tertiles of the inflammation marker MCP-1 (≥40 pmol/L). Here, CCL2 is linked to type 2 diabetes mellitus.